206 related articles for article (PubMed ID: 18307293)
1. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
Slee DH; Moorjani M; Zhang X; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Jalali K; Sai Y; Zuo Z; Yang C; Wen J; O'Brien Z; Petroski R; Saunders J
J Med Chem; 2008 Mar; 51(6):1730-9. PubMed ID: 18307293
[TBL] [Abstract][Full Text] [Related]
2. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.
Slee DH; Chen Y; Zhang X; Moorjani M; Lanier MC; Lin E; Rueter JK; Williams JP; Lechner SM; Markison S; Malany S; Santos M; Gross RS; Jalali K; Sai Y; Zuo Z; Yang C; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J
J Med Chem; 2008 Mar; 51(6):1719-29. PubMed ID: 18307292
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
Slee DH; Zhang X; Moorjani M; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Wen J; O'Brien Z; Saunders J
J Med Chem; 2008 Feb; 51(3):400-6. PubMed ID: 18189346
[TBL] [Abstract][Full Text] [Related]
4. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
5. N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.
Lanier MC; Moorjani M; Luo Z; Chen Y; Lin E; Tellew JE; Zhang X; Williams JP; Gross RS; Lechner SM; Markison S; Joswig T; Kargo W; Piercey J; Santos M; Malany S; Zhao M; Petroski R; Crespo MI; Díaz JL; Saunders J; Wen J; O'Brien Z; Jalali K; Madan A; Slee DH
J Med Chem; 2009 Feb; 52(3):709-17. PubMed ID: 19140664
[TBL] [Abstract][Full Text] [Related]
6. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Higgins GA; Cohen-Williams ME; Varty GB; Tulshian DB
Bioorg Med Chem Lett; 2005 Aug; 15(16):3675-8. PubMed ID: 15982882
[TBL] [Abstract][Full Text] [Related]
7. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
[TBL] [Abstract][Full Text] [Related]
8. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.
Gillespie RJ; Bamford SJ; Botting R; Comer M; Denny S; Gaur S; Griffin M; Jordan AM; Knight AR; Lerpiniere J; Leonardi S; Lightowler S; McAteer S; Merrett A; Misra A; Padfield A; Reece M; Saadi M; Selwood DL; Stratton GC; Surry D; Todd R; Tong X; Ruston V; Upton R; Weiss SM
J Med Chem; 2009 Jan; 52(1):33-47. PubMed ID: 19072055
[TBL] [Abstract][Full Text] [Related]
10. Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC; Rassnick S; Chakravarty D; Wallace N; Ault M; Crooke J; Barbay JK; Wang A; Leonard K; Powell MT; Alford V; Hall D; Rupert KC; Heintzelman GR; Hansen K; Bullington JL; Scannevin RH; Carroll K; Lampron L; Westover L; Russell R; Branum S; Wells K; Damon S; Youells S; Beauchamp D; Li X; Rhodes K; Jackson PF
Bioorg Med Chem Lett; 2010 May; 20(9):2868-71. PubMed ID: 20338760
[TBL] [Abstract][Full Text] [Related]
11. The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.
Matasi JJ; Caldwell JP; Hao J; Neustadt B; Arik L; Foster CJ; Lachowicz J; Tulshian DB
Bioorg Med Chem Lett; 2005 Mar; 15(5):1333-6. PubMed ID: 15713381
[TBL] [Abstract][Full Text] [Related]
12. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.
Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA
Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
15. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Cohen-Williams ME; Varty GB; Tulshian DB
Bioorg Med Chem Lett; 2005 Aug; 15(16):3670-4. PubMed ID: 15978806
[TBL] [Abstract][Full Text] [Related]
16. Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC; Rassnick S; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Scannevin RH; Magliaro B; Westover L; Carroll K; Lampron L; Russell R; Branum S; Wells K; Damon S; Youells S; Li X; Osbourne M; Demarest K; Tang Y; Rhodes K; Jackson PF
Bioorg Med Chem Lett; 2010 May; 20(9):2864-7. PubMed ID: 20347304
[TBL] [Abstract][Full Text] [Related]
17. 2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability.
Moorjani M; Luo Z; Lin E; Vong BG; Chen Y; Zhang X; Rueter JK; Gross RS; Lanier MC; Tellew JE; Williams JP; Lechner SM; Malany S; Santos M; Crespo MI; Díaz JL; Saunders J; Slee DH
Bioorg Med Chem Lett; 2008 Oct; 18(20):5402-5. PubMed ID: 18835161
[TBL] [Abstract][Full Text] [Related]
18. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Jordan AM; Knight AR; Lerpiniere J; Misra A; Pratt RM; Roffey J; Stratton GC; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2924-9. PubMed ID: 18411049
[TBL] [Abstract][Full Text] [Related]
19. Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives.
Saku O; Saki M; Kurokawa M; Ikeda K; Takizawa T; Uesaka N
Bioorg Med Chem Lett; 2010 Feb; 20(3):1090-3. PubMed ID: 20034788
[TBL] [Abstract][Full Text] [Related]
20. Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Zhang X; Tellew JE; Luo Z; Moorjani M; Lin E; Lanier MC; Chen Y; Williams JP; Saunders J; Lechner SM; Markison S; Joswig T; Petroski R; Piercey J; Kargo W; Malany S; Santos M; Gross RS; Wen J; Jalali K; O'Brien Z; Stotz CE; Crespo MI; Díaz JL; Slee DH
J Med Chem; 2008 Nov; 51(22):7099-110. PubMed ID: 18947224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
